[-] Show simple item record

dc.contributor.authorGeurin, Michael D.
dc.contributor.authorSt. Anna, Leilani
dc.date.issued2010-12eng
dc.description.abstractThere is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting. (Strength of Recommendation: B, based on a single randomized controlled trial). Effects of TZD therapy on nonglycemic markers of metabolic syndrome are inconsistent compared with the effects of other hypoglycemic medications.en_US
dc.identifier.citationAmerican Family Physician, 82(128) 2010: [1553]-1554.en_US
dc.identifier.urihttp://hdl.handle.net/10355/11924
dc.publisherFamily Physicians Inquiries Networken_US
dc.relation.ispartofClinical Inquiries, 2010 (MU)en
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network
dc.subjectcardiac eventsen_US
dc.subjectpreventative measuresen_US
dc.subject.lcshCardiovascular emergenciesen_US
dc.titleThiazolidinedione Therapy for Managing Metabolic Syndromeen_US
dc.typeArticleen_US


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record